Interventional Management of Stroke ( IMS ) III is a randomized , parallel arm trial comparing the approach of intravenous tissue-type plasminogen activator followed by endovascular treatment with intravenous tissue-type plasminogen activator alone in patients with acute ischemic stroke presenting < 3 hours of symptom onset .